Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Metabolon and Harvard-Partners ink warfarin deal
April 2008
SHARING OPTIONS:

RESEARCH TRIANGLE PARK, N.C.Metabolon Inc., a metabolomics-driven biomarker discovery and analysis company, has teamed up with Boston-based Harvard-Partners Center for Genetics and Genomics (HPCGG), a collaborative program dedicated to promoting genetics and genomics in research and clinical medicine. Under their agreement, they will develop an improved diagnostic test for enabling a more accurate dosing of warfarin. Warfarin, a blood thinning agent prescribed extensively during the last 50 years, reportedly causes more than 700,000 adverse events per year due to improper dosing.




 

Back



PAGE UTILITIES


CONTACT US
DDNEWS
478 Bay Street, Suite A213
Midland, Ontario, Canada L4R 1K9
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.